Humoral and cellular immune response to elastin in patients with systemic sclerosis.
The humoral immune response against elastin and collagen was studied in parallel with the delayed type hypersensitivity (DTH) reaction to elastin and the percentage of lymphocyte subpopulations in peripheral blood in 20 patients with systemic sclerosis (SSc). An increase of anti-elastin antibodies of all subclasses was found with a significant prevalence of IgE and IgA antibodies. The profile of anti-collagen type I and type IV antibodies showed an increase of IgE isotypes. In 25% of the patients (5 out of 20) positive DTH reactions to elastin were observed as compared to the negative skin reactions in all control individuals. At the same time a significant hyporeactivity to common bacterial and mould antigens was found in 40% of the patients (versus 16% in the control group) which could be an explanation for the low incidence of positive anti-elastin DTH reaction. The DTH hyporeactivity in SSc cases was in contrast with the increased percentage of CD4 T cells (58.4 vs. 42.0) and increased CD4/CD8 ratio (2.5 vs. 1.5) in the peripheral blood of the patients. This finding together with the increased IgE antibodies to elastin and collagen type I and type IV might suggest a possible shift of the immune balance towards the Th2 type of immune response. This is in line with the increased CD8+CD57+ cells which correlated with the highest number of other parameters studied - disease duration, total skin score, IgE anti-elastin antibodies, IgG anti-collagen type I antibodies, CD4/CD8 ratio and CD19 B cells. The results of this study demonstrated the existence of both humoral and cell-mediated immune response against elastin in SSc patients. However, we could not define whether this was an essential part of pathogenetic mechanisms or a secondary phenomenon reflecting the extent of the damage of connective tissue.
Daskalova
M
M
Department of Biology and Immunology, Medical University, Pleven.
Taskov
H
H
Dimitrova
E
E
Baydanoff
S
S
D000328:Adult; D000368:Aged; D000917:Antibody Formation; D000918:Antibody Specificity; D018941:Antigens, CD19 / Q000032:analysis; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D001324:Autoantigens / Q000276:immunology*; D001327:Autoimmune Diseases / Q000276:immunology*; D016175:B-Lymphocyte Subsets / Q000276:immunology; D016516:CD4-CD8 Ratio; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018959:CD57 Antigens / Q000032:analysis; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003094:Collagen / Q000276:immunology; D004549:Elastin / Q000276:immunology*; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular; D007132:Immunoglobulin Isotypes / Q000097:blood / Q000276:immunology*; D016130:Immunophenotyping; D016131:Lymphocyte Subsets / Q000276:immunology*; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000276:immunology*; D012882:Skin Tests
D018941:Antigens, CD19; D001323:Autoantibodies; D001324:Autoantigens; D018959:CD57 Antigens; D007132:Immunoglobulin Isotypes; D003094:Collagen; D004549:Elastin